Mutations of the Fibroblast Growth Factor Receptor 3 (FGFR3) gene have been implicated in a series of skeletal dysplasias including hypochondroplasia, achondroplasia and thanatophoric dysplasia. The severity of these diseases ranges from mild dwarfism to severe dwarfism and to perinatal lethality, respectively. Although it is considered that the mutations give rise to constitutively active receptors, it remains unclear how the different mutations are functionally linked to the severity of the different pathologies. By examining various FGFR3 mutations in a HEK cell culture model, including the uncharacterized X807R mutation, it was found that only the mutations affecting the intracellular domain, induced premature receptor phosphorylation and inhibited receptor glycosylation, suggesting that premature receptor tyrosine phosphorylation of the native receptor inhibits its glycosylation. Moreover, these mutations appeared to be associated with elevated receptor signaling in the Golgi apparatus. In conclusion, although pathological severity could not be correlated with a single factor arising from FGFR3 mutations, these results suggest that intracellular domain mutations define a distinct means by which mutated FGFR3 could disrupt bone development.
Introduction
Fibroblast Growth Factor Receptor 3 (FGFR3) belongs to a family of four genes (FGFR1-4) coding for receptor tyrosine kinases [1] . These proteins constitute a family of structurally related proteins exhibiting an extracellular domain composed of three immunoglobulin-like domains, an acid box, a single transmembrane domain and a split tyrosine kinase (TK) domain [1] .
FGF receptor dimerization and phosphorylation is induced through the binding of its ligand (FGF) in the presence of soluble or cell-surface heparan sulfate proteoglycans [2] [3] [4] [5] [6] . The dimer state is stabilized by a conformational change in the extracellular domain [7] . As a result the two monomers come into contact. This stimulates catalytic activity resulting in transphosphorylation of key tyrosine residues in the cytoplasmic domain of the receptor that serve as docking sites for the adaptor proteins and effectors that propagate FGFR3 signals via different signaling cascades [8, 9] .
FGF signaling through FGFR3 is implicated in the regulation of many cellular processes including proliferation, differentiation, migration, wound healing, and angiogenesis [10, 11] . Mutations in FGFR3 have been shown to be responsible for a variety of skeletal dysplasias [12] of increasing severity, including achondroplasia (ACH) which is the most common form of human dwarfism [13, 14] , the milder disorder hypochondroplasia (HCH) [15, 16] and the more severe thanatophoric dysplasia types I and II (TD I and TDII) [13, 17, 18] . The thanatophoric dysplasia subdivision arises from the presentation of curved femurs in TDI but not in TDII. TDIs caused by the K650M mutation can also be associated with Severe Achondroplasia with Developmental Delay and Acanthosis Nigricans (SADDAN) [19] . These FGFR3 mutations appear to arise from spontaneous missense neo-mutations [20] .
The molecular basis underlying the various chondrodysplasias is thought to be a consequence of the constitutive activation of mutant receptors [21] [22] [23] . These dominant active mutations in FGFR3 inhibit endochondral bone growth and cause ACH or, TD in murine transgenic models [24] [25] [26] .
A number of mechanisms have been proposed to explain how the mutations affect FGFR3 activation. These include increased ligand-binding affinity or decreased ligand-mediated receptor down-regulation in the case of G380R [27] and stabilized ligandinduced dimers in the case of R248C (TDI) [22, 28] . Activating mutations in the TK domain, such as is the case of the K650N, K650M and K650E mutations (corresponding to HCH, TDI and TDII, respectively), lead to ligand-independent receptor activation and constitutive receptor tyrosine phosphorylation [22] . More recently, two mutations in the murine equivalent of K650E have been found to inhibit FGFR3 trafficking to the plasma membrane from the endoplasmic reticulum [29, 30] . However it remains unclear how these mechanistic aberrations relate to disease severity.
The aim of this study was to compare two attributes of mutant receptor biochemistry (tyrosine phosphorylation and receptor glycosylation), and the pathology with which the mutation has been associated. The study analyzed wild type and seven mutated FGFR3s including the uncharacterized X807R mutation [31] , in a HEK cell culture model. Even though all the mutated receptors were found to have an elevated level of phosphorylated tyrosine, these levels did not appear to correlate with disease severity. Tyrosine phosphorylation was identified on native and partially glycosylated isoforms for the K650N, K650M, K650E and X807R mutations and appeared to disrupt glycosylation. However, the degree of defective glycosylation did not correlate with disease severity. The three K650 mutations and the X807R mutation elicited a high degree of intracellular tyrosine phosphorylation primarily associated with Rab6-positive structures suggesting the existence of ectopically activated signaling cascades associated with the Golgi apparatus. The study therefore finds that disease severity of chondrodysplasias cannot solely be attributed to receptor activation or receptor activation at the plasma membrane.
Materials and methods

Generation of human FGFR3 constructs
Full length human wild type FGFR3 cDNA was kindly provided by Dr. M. Hayman (New York). Single point mutations were generated by site-directed mutagenesis (Quikchange® Site-Directed Mutagenesis, Stratagene). Enzymes were purchased from New England Biolabs, Roche Diagnostics and Invitrogen. Reverse transcriptase-PCR (First Strand Synthesis, Roche Diagnostics) was performed on patient RNA using primer sets R248C/Y373C-P1/R248C/Y373C-P2 and G380R-P1/G380R-P2. Site-directed mutagenesis for K650N, K650M and K650E and X807R was performed on wild type FGFR3. All constructs were cloned into pCDNA3.1 (Invitrogen, Europe). PCR and site-directed mutagenesis primers are listed in Supplementary Table 1 . The presence of mutations was confirmed by sequencing.
Western blotting (WB) and immunoprecipitation (IP)
Transfected cells were lysed in RIPA Buffer (50 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% Nonidet-P40, 0.5% sodium deoxycholate, supplemented with protease and phosphatase inhibitors). For Western blotting, 20 μg of cell lysate in RIPA buffer were used. Immunoprecipitation was performed by incubating 1 μg rabbit anti-FGFR3 (polyclonal against the cytoplasmic domain)/100 μg protein with protein G agarose (Roche). Immunoblotting: anti-FGFR3 (Sigma) or mouse anti-phosphotyrosine (Cell Signaling) were used at a concentration of 1:2000; secondary antibodies anti-rabbit or anti-mouse HRP (Amersham) were used at a concentration of 1:10000 and were detected by chemiluminescence (ECL, Amersham Pharmacia Biotech). Where necessary, PVDF membranes were stripped in 2% SDS, 100 mM β-mercaptoethanol, 50 mM Tris, pH 6.8.
Glycosidase treatments
Anti-FGFR3 immunoprecipitates were resuspended in 50 mM sodium citrate (pH 5.5), 1% SDS, 1% β-mercaptoethanol. The sample was divided proportionally for untreated or EndoH (endoglycosidaseH, Roche) and PNgaseF (peptide: N-glycosidase F, Roche) treatments, and used according to the manufacturer's instructions.
Cell culture, transfections and treatments
Human Embryonic Kidney cells (HEK) stably expressing the vitronectin receptor (293 VnR) were provided by Dr. R. Baron (Yale University). Cells were incubated in DMEM supplemented with 10% FCS (Invitrogen), and antibiotics. Transfection of constructs into cells at 50-80% confluency using Fugene6 (Roche) was performed according to the manufacturer's instructions. Brefeldin A (BFA) treatment: 5 μg/ml for 2 h at 37°C (Epicentre Technologies; TEBU France). Nocodazole treatment: 10 μg/ml 2 h at 37°C (BIOMOL; TEBU, France). The tyrosine kinase inhibitor Sugen5402 (gift from G. Mc Mahon, SUGEN) was dissolved in DMSO and used at 25 μM overnight. Control cells were incubated with DMSO alone. Tunicamycin treatment (5μg/ml; Sigma Aldrich) was overnight in DMEM supplemented with 10% FCS.
Immunofluorescence
Transfected cells were fixed in 4% PFA for 20 min, permeabilized in 0.1% TritonX-100/PBS and blocked in 10% normal sheep serum. Incubation with primary antibodies; anti-FGFR3 at 1:400; anti-phosphotyrosine at 1:200; rabbit anti-calnexin at 1:100, (Sigma); mouse anti-GM130 at 1:100, (BD Transduction Laboratories); rabbit anti-rab6, at 1:100 (Tebu, France); rabbit anti-Sec31, at 1:100 (a gift from Prof. W. Hong), was for 1 h at room temperature. Incubation with secondary antibodies Alexa488 and Alexa568 at 1:400 (Molecular Probes) was for 1 h at room temperature. For anti-Rab6; after fixing in PFA, cells were pre-incubated in 50 mM NH 4 Cl/PBS for 10 min, with antibody incubation in 0.05% saponin and 0.2% normal sheep serum in PBS.
Image analysis and statistics
Experiments were performed on three or more independent occasions. The quantification of Western blotting was performed using NIH Image. Statistical differences were identified by application of the Student t test. The variations from the mean values shown are equal to the Standard Deviations from these respective means. Immunofluorescence images were selected as good representatives of the experimental condition.
Results
Glycosylation of FGFR is affected by the K650 mutations
The FGFR3 mutations associated with bone growth disorders are found in different domains and depicted in Fig. 1A . These include the intracellular domain (K650N/HCH, K650M/TDI, K650E/TDII, X807R/TDI), the transmembrane domain (G380R/ACH) and the extracellular domain (R248C/TDI, Y373C/TDI). The mutation arising from the stop codon read through (X807R/TDI) is predicted to generate a protein the size of FGFR3 plus 141 amino acid residues. The consequences of these mutations were analyzed in HEK cells by transient transfection of FGFR3 expression plasmids.
Twenty-four hours post-transfection, FGFR3 protein with three mobilities was detected by Western blot analysis of FGFR3 immunoprecipitates from transfected cell extracts (Fig. 1B) . Glycosidase treatments of the protein extracts revealed the wild type and each of the mutant FGFR3 proteins (R248C, G380R, Y373C K650N, K650M, K650E) exist as an unglycosylated form (highest mobility, 105 kDa), an EndoH glycosidasesensitive form (intermediate mobility; 115 kDa) and an EndoH insensitive but PNGase-sensitive form (lowest mobility, 130 kDa). This suggested that FGFR3 was subject to progressive glycosylation from native to fully mature receptor. This was confirmed by treating the WT and K650M FGFR3 transfected cells with the N-glycosylation inhibitor tunicamycin. The inhibition of glycosylation reduced the level of the 115 kDa and 130 kDa isoforms compared with the untreated controls, 24 h post-transfection (Fig. 1C) .
By quantifying the levels of the different FGFR3 glycosylated isoforms at 24 and 48 h, it was found that the relative levels of the non-glycosylated receptors had declined and the fully glycosylated receptors had increased at 48 h compared with 24 h post transfection (p < 0.05; Fig. 1D ). The proportional level of fully glycosylated receptors found with the WT receptor at 24 h (38 ± 8%, n = 15) was similar to that found with R248C (35 ± 16%, n = 8), G380R (36 ± 12%, n = 5), Y373C (37 ± 11%, n = 6) mutations. However the proportional level of fully glycosylated receptors found with K650N (24 ± 9%, n = 5), K650M (7 ± 4%, n = 10) and K650E (4 ± 4%, n = 10) was significantly less than that found with the WT, whereas the proportional level of nonglycosylated K650M (31 ± 8%) and K650E (33 ± 15%) receptors, was significantly greater than that found with the WT (12 ± 7%). This suggested that mutations associated with amino acid K650 of the intracellular domain inhibited glycosylation and the mutations that occur in the transmembrane or extracellular domains do not inhibit glycosylation.
Receptor phosphorylation is greater for FGFR3 with intracellular mutations
To examine the relationship between glycosylation and receptor tyrosine phosphorylation, anti-FGFR3 immunoprecipitates of transfected cells were probed with a phosphotyrosine antibody on Western blots (Fig. 1E) . A low level of phosphotyrosine was detected on the wild type receptor. A marginally greater level of tyrosine phosphorylated FGFR3 was found with the G380R, R248C and Y373C mutants. The level of tyrosine The levels of the native and differently glycosylated WT, G380R, R248C, Y373C, K650N, K650M and K650E FGFR3 isoforms were examined at 24 and 48 h by Western blot (upper panels). The relative levels of the native and differently glycosylated isoforms from at least five experiments were quantified at 24 h (lower graphics). The asterisks mark the significantly lower relative levels of the fully glycosylated isoforms compared with that of the WT (*p < 0.01; **p < 0.001). (E) The detection of tyrosine phosphorylation on the FGFR3s. WT, G380R, R248C, Y373C, K650N, K650M and K650E FGFR3s were immunoprecipitated by anti-FGFR3 and examined by Western blot with anti-FGFR3 or anti-phosphotyrosine. (F) WT and K650M FGFR3s were treated with Sugen5402 (tyrosine kinase inhibitor) and examined by Western blotting of anti-FGFR3 immunoprecipitations. Sugen5402 treatment reduced tyrosine phosphorylation and increased the relative level of the fully-glycosylated isoform of the K650M mutant. phosphorylated FGFR3 was greater again with the K650 mutants, where K650M > K650E > K650N. Moreover phosphotyrosine was detected primarily on the fully glycosylated isoforms of the WT, G380R, R248C, Y373C FGFRs whereas phosphotyrosine was also detected on the non-and partially glycosylated K650 mutant isoforms. These results suggested that tyrosine phosphorylation of the K650 mutants in their nonor partially-glycosylated forms, inhibits their further glycosylation. This is especially so for K650M and K650E, and less marked for K650N. This suggestion was supported by analyzing cells transfected with either the WT or K650M mutant FGFR3s following treatment with the tyrosine kinase inhibitor Sugen5402 (Fig. 1F) . Following Western blot of FGFR3 immunoprecipitates, it was found that the level of tyrosine phosphorylated FGFR3 was strongly reduced, although some tyrosine phosphorylated FGFR3 was detected with the K650M mutant (Fig. 1F) . The reduction of tyrosine phosphorylation of the K650M mutant FGFR3 was associated with a large relative increase in the level of fully glycosylated isoform. Such a relative increase in the level of fully glycosylated isoform was not detected in cells transfected with the wild type receptor.
The degree of glycosylation and of tyrosine phosphorylation of the FGFR3 mutants were compared with pathology severity (Table 1) . Pathology severity was ranked in accordance to what has been described for the long bone dysplasia, placing the TDI and TDII with equal but most severe rank [32, 33] . It was found that there was no simple or significant correlation between these factors and the severity of the disease pathology associated with the different mutations. However the analysis suggested that the K650 mutations function differently to those mutations affecting the transmembrane or extracellular domains where the pathology severity is positively correlated with the degree of disrupted receptor glycosylation (r 2 = 0.97).
The X807R mutation affects FGFR3 glycosylation
The FGFR3 stop codon read-through mutation X807R, was identified in the TDI pathology but its functional relationship to the pathology is not known. Three FGFR3 isoforms of differing mobilities were detected in cells transfected with the X807R mutant (Fig. 2B) . The X807R mutant was found to exist as unglycosylated and glycosylated forms. The intermediate mobility isoform was both PNGase and EndoH sensitive and the lowest mobility isoform was PNGase sensitive but endoH insensitive. The size of the X807R isoforms suggested that they all included the predicted 141 amino residue read-through. By quantifying the levels of the different isoforms 24 h posttransfection, it was found that the relative level of fully glycosylated isoform (12 ± 9%, n = 8) was similar to what was found with the K650M and K650E mutants and significantly lower than what was found with the WT receptor ( Fig. 2C and see  Fig. 1D ). Also consistent with an inhibition of glycosylation, the relative level of non-glycosylated X807R mutant receptor (49 ± 15%) was significantly greater than that found with the WT. The X807R mutant was also found to be tyrosine phosphorylated on the non-and partially-glycosylated isoforms (Fig. 2D) . Therefore this suggested that the X807R confers a constitutively active status to FGFR3. Moreover X807R was found have similar characteristics to the other intracellular domain mutations (K650N, K605E and K650M) suggesting that the intracellular mutations enable tyrosine phosphorylation prior to glycosylation.
Greater levels of phosphotyrosine-positive puncta occur with the intracellular FGFR3 mutations
The process of protein glycosylation is related to trafficking through the endoplasmic reticulum and Golgi apparatus. Typically, the glycosylation that is EndoH sensitive takes place in the endoplasmic reticulum whereas glycosylation insensitive to EndoH takes place in the Golgi apparatus. Using immunofluorescence to examine cells 24 h post-transfection, it was found that the wild type and the mutant FGFR3s were associated with intracellular structures throughout the cytoplasm. In every case there was some co-localization of these structures and punctate structures detected by the Golgi marker antibody, GM130 (Fig.  2E ). This suggested that the resistance of the K650N, K650E, K650M and X807R mutants to complete glycosylation was not because they were prevented from reaching the Golgi apparatus.
Given that receptor tyrosine phosphorylation was also found to inhibit receptor glycosylation, a phosphotyrosine antibody was used for immunofluorescence (Fig. 3A) . High phosphotyrosine levels were essentially associated with FGFR3 transfected cells (with a low level occasionally detectable in untransfected cells). The punctate structures detected by the phosphotyrosine antibody also co-localized with some of the intracellular structures detected by the FGFR3 antibody suggesting that these punctate structures include tyrosine phosphorylated FGFR3. The intensity and the extent of phosphotyrosinepositive puncta appeared greater in the K650N, K650E, K650M and the X807R mutants compared with the other mutants and the wild type FGFRs (Fig. 3B) .
Phosphotyrosine-positive puncta are distinctly associated with the Golgi apparatus
In order to attempt to identify whether the phosphotyrosine activity of FGFR3 is associated with subcellular sites of glycosylation, the immunodetection by anti-phosphotyrosine was compared with markers of the ER (calnexin), of ER exit (sec31) [34] and of the Golgi apparatus (rab6) [35] (Fig. 4) . Calnexin was associated with structures throughout the cytoplasm as expected for a protein expressed in the ER (it retains unfolded or unassembled N-linked glycoproteins in the ER). Few of the low level of phosphotyrosine-positive puncta co-localized with cells transfected with the wild type FGFR3. However there appeared to be proportionally more co-localization of phosphotyrosine-positive puncta with calnexin in the K650M and X807R mutants. Sec31 was detected as punctate structures throughout the cytoplasm as expected for a protein involved in the transport of proteins from the ER to the Golgi apparatus. There was little colocalization of phosphotyrosinepositive puncta with sec31 in the cells transfected with wild type and X807R FGFR3s, but some co-localization was seen in the cells transfected with K650M. Rab6-positive puncta were identified as being restricted to a portion of the cytoplasm proximal to an aspect of the nucleus expected for a protein associated with different parts of the Golgi (medial, trans-Golgi network and post-Golgi vesicles). In all FGFR3-transfected cells a high proportion of phosphotyrosine-positive puncta appeared co-localized with rab6. Therefore, phosphotyrosine activity arising from FGFR3 transfection appeared mainly associated with the Golgi apparatus in comparison to the other intracellular structures examined. 
Nocodazole treatment redistributes phosphotyrosine-positive puncta
To further examine whether the phosphotyrosine-positive puncta were mainly associated with the Golgi apparatus, transfected cells were treated with nocodazole. Nocodazole affects microtubule stability and therefore disrupts Golgi apparatus positioning in the cell without affecting its function. Treatment with nocadazole did not appear to affect the relative level of fully glycosylated receptor in cells transfected with wild type or K650M FGFR3s (Fig. 5A) . Analysis by immunofluorescence found that nocodazole treatment led to phosphotyrosine-positive puncta being more scattered throughout the cytoplasm in the cells transfected with wild type and K650M and X807R FGFR3s (Fig. 5B) . Therefore these results further support that the phosphotyrosine activity associated with FGFR3 transfection is associated with the Golgi apparatus.
4.7.
BrefeldinA inhibits glycosylation and the number of phosphotyrosine-positive puncta BFA reversibly disrupts Golgi apparatus function by inhibiting the anterograde transport from the endoplasmic reticulum to the Golgi apparatus. BFA treatment reduced the relative level of the fully glycosylated FGFR3 especially notable in the cells transfected with the wild type, G380R, Y373C and K650N receptors where the levels of the fully glycosylated isoforms in the untreated samples were relatively high (Fig. 5C ). As expected, this suggested that the glycosylation processing was unable to be completed because BFA was preventing FGFR3 from leaving the ER on its route to the Golgi apparatus.
Analysis by immunofluorescence suggested that the level of intensity and number of phosphotyrosine-positive puncta were dramatically reduced following treatment with BFA in FGFR3-transfected cells (Fig. 5D ). This again suggested that the induction of phosphotyrosine levels primarily occurs post-ER and hence in the Golgi apparatus. However, despite the generally large reduction of phosphotyrosine immunoreactivity, more was found in those cells transfected with the three K650 mutants and with X807R compared with the cells transfected with the wild type, G380R and Y373C. This suggested that the phosphotyrosine detected in the cells treated with BFA and transfected with the K650 and X807R mutants may have arisen from those receptors that have yet to be glycosylated, as detected by immunoprecipitation (Figs. 1E and 2C ).
Discussion
Spontaneous missense neo-mutations in FGFR3 are responsible for chondrodysplasias such as HCH, ACH, TDI and TDII. Several mutations affecting particular amino acid residues of the receptor have now been identified. The analysis of the X807R mutation further supports the idea that these mutations promote receptor tyrosine phosphorylation [32] , and presumably promote concomitant tyrosine phosphorylation of other protein substrates. The X807R represents a different type of mutation compared with the other characterized mutations, in that due to a read-through of the stop codon. The resultant predicted protein sequence has an elongated C-terminal domain. This additional C-terminal domain may function by stabilizing tyrosine phosphorylation, perhaps by inducing some form of conformational change that is similar to that described for the K650 mutations [21, 26] . The detection of tyrosine phosphorylation was found in a similar fashion to that of the K650 mutated receptors, being found on the non-and partially-glycosylated X807R mutated receptor.
Further receptor tyrosine phosphorylation with any of the mutated receptors, could not be provoked by the addition of FGF ligand suggesting a limitation of this HEK model. However the fact that tyrosine phosphorylation was detected with all the receptors suggested that they have the capacity of being phosphorylated in the absence of ligand. Another potential problem with a transient transfection model is that over-expressed proteins could accumulate in the ER. This may have occurred with this study as the immunodetection of the WT and mutated FGFR3s were found in structures throughout the cytoplasm and was similar to that of the ER marker calnexin (compare anti-FGFR3 in Figs. 2 and 3 with that of anti-calnexin in Fig. 4) . Some of these structures though, were also marked by the Golgi marker GM130, suggesting that all the receptors could traffic from the ER to the Golgi apparatus. This trafficking step is indicative of correct receptor folding and N-glycosylation [36] . By quantifying the FGFR3 isoform levels of the WT and mutated receptors at 24 and 48 h post-transfection suggested that the correct progression of glycosylation could occur in this model, with the relative level of the non-glycosylated FGFR3 isoform decreasing in all the receptors when examined at 48 h. Moreover this analysis indicated that these glycosylation steps were significantly disrupted only in the cells transfected with K650N, M and E, and X807R mutated FGFR3s.
The western analysis also found that those mutations located in the intracellular domain resulted in the tyrosine-phosphorylation of non-and partially-glycosylated receptor isoforms. This biochemical difference was corroborated by the immunofluorescence analysis, where it was found that these receptors also appeared associated with an enhanced level of tyrosinephosphorylated proteins in intracellular structures that had properties consistent with being components of the Golgi apparatus. This suggested that those mutations located in the intracellular domain provoke premature phosphorylation of the de novo receptor.
This premature phosphorylation also appeared to inhibit receptor glycosylation, concurring with previous analyses of the murine equivalents of the K650 mutations [29, 30] . In contrast to these previous studies where it has been suggested that these constitutively active mutated murine receptors accumulate in the ER, the results here suggest a model where the constitutively active human receptors, mutated in the intracellular domain, accumulate in the Golgi apparatus, where they promote further tyrosine phosphorylation. In this study phosphotyrosine was used as a readout of FGFR3 activity, whereas in previous studies, particular tyrosine phosphorylated FGFR3 targets such as Stat1, Stat3, Stat5, Jak1 and ERK1/2 were analysed [30, 37] . One of these studies suggested that murine equivalents of K650 M and E phosphorylate these proteins in the ER because their detection was insensitive to BFA treatment. In this study, BFA did not completely extinguish the immunodetection of phosphotyrosine and therefore the phosphotyrosine antibody may have detected these FGFR3 targets. One potential FGFR3 signaling molecule post-ER in the case of K650N alone, could be Stat1 [30] . The murine equivalent of K650N FGFR3 was found to stimulate Stat1 phosphorylation with and without the post-Golgi trafficking inhibitor monensin, but was found not stimulate Stat1 phosphorylation with BFA treatment (unlike the murine equivalents of K650 M and E) [30, 37] . Therefore this suggests that the phosphotyrosine detected in the Golgi by immunofluorescence in this study, especially in the cases of K650M, E and X807R, is either mainly derived from the FGFR3 itself or from other FGFR3 phosphotyrosine targets yet to be identified.
Hence, the receptors with intracellular domain mutations define a distinct means by which mutated FGFR3 can disrupt bone development, through enhanced and ectopic signaling emanating from the Golgi apparatus. This may explain why the correlation between the degree disrupted receptor glycosylation and pathology severity may only hold for the K650 mutated receptors. Moreover this study predicts that the X807R mutations gives rise to bone dysplasia by a similar mechanism to that found with the K650 mutations. It also seems clear that other factors in addition to tyrosine phosphorylation and disrupted receptor glycosylation are implicated in the severity of the disease; and one additional factor includes the intracellular localization of receptor activity to the Golgi apparatus.
